Top 5 Stocks to Buy Now
→ 2,000 missiles didn't hit Iran. They hit China. (From Behind the Markets) (Ad)tc pixel Free GRDN Stock Alerts

Guardian Pharmacy Services (GRDN) Financials

Guardian Pharmacy Services logo
$38.74 +0.41 (+1.08%)
Closing price 06/25/2026 03:59 PM Eastern
Extended Trading
$38.88 +0.13 (+0.35%)
As of 04:41 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Guardian Pharmacy Services

Annual Income Statements for Guardian Pharmacy Services

This table shows Guardian Pharmacy Services' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 0.00 -110 49
Consolidated Net Income / (Loss)		 38 -71 49
Net Income / (Loss) Continuing Operations		 38 -71 49
Total Pre-Tax Income 		38 -66 73
Total Operating Income		 41 -63 73
Total Gross Profit		 208 244 293
Total Revenue		 1,046 1,228 1,449
Operating Revenue		 1,046 1,228 1,449
Total Cost of Revenue		 838 984 1,156
Operating Cost of Revenue		 838 984 1,156
Total Operating Expenses		 167 307 220
Selling, General & Admin Expense		 167 307 220
Total Other Income / (Expense), net		 -3.23 -3.56 0.72
Interest Expense		 2.86 3.28 0.67
Other Income / (Expense), net		 -0.37 -0.28 1.39
Income Tax Expense		 0.00 4.56 24
Net Income / (Loss) Attributable to Noncontrolling Interest		 38 39 -0.26
Basic Earnings per Share		 $0.00 ($1.77) $0.00
Weighted Average Basic Shares Outstanding		 0.00 62.01M 0.00
Diluted Earnings per Share		 $0.00 ($1.77) $0.00
Weighted Average Diluted Shares Outstanding		 0.00 62.01M 0.00
Weighted Average Basic & Diluted Shares Outstanding		 - 63.29M 63.32M

Quarterly Income Statements for Guardian Pharmacy Services

This table shows Guardian Pharmacy Services' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 0.00 0.00 0.00 -122 12 9.45 9.03 9.82 21 13
Consolidated Net Income / (Loss)		 -7.00 7.10 16 -106 12 9.27 8.83 9.59 21 14
Net Income / (Loss) Continuing Operations		 -7.00 7.10 16 -106 12 9.27 8.83 9.59 21 14
Total Pre-Tax Income 		-7.00 7.10 16 -106 16 13 13 17 31 18
Total Operating Income		 -6.33 7.93 17 -105 17 13 13 16 31 18
Total Gross Profit		 52 55 61 61 67 64 68 75 86 76
Total Revenue		 263 275 300 314 339 329 344 377 398 337
Operating Revenue		 263 275 300 314 339 329 344 377 398 337
Total Cost of Revenue		 211 220 239 254 271 265 276 303 312 260
Operating Cost of Revenue		 211 220 239 254 271 265 276 303 312 260
Total Operating Expenses		 59 47 44 165 50 51 56 58 55 59
Selling, General & Admin Expense		 59 47 44 165 50 51 56 58 55 59
Total Other Income / (Expense), net		 -0.67 -0.84 -1.16 -1.03 -0.53 0.10 0.01 0.28 0.34 0.62
Interest Expense		 0.72 0.77 1.07 1.03 0.42 0.17 0.17 0.16 0.16 0.15
Other Income / (Expense), net		 0.05 -0.07 -0.09 -0.00 -0.11 0.27 0.18 0.44 0.50 0.77
Income Tax Expense		 0.00 0.00 0.00 0.18 4.38 3.83 3.76 7.04 9.83 4.75
Net Income / (Loss) Attributable to Noncontrolling Interest		 -7.00 7.10 16 16 -0.10 -0.18 -0.20 -0.23 0.34 0.25
Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($1.77) $0.15 $0.15 $0.16 ($0.46) $0.21
Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 0.00 62.01M 62.04M 62.05M 62.12M 0.00 63.32M
Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($1.77) $0.15 $0.14 $0.15 ($0.44) $0.21
Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 0.00 62.01M 62.91M 63.20M 63.43M 0.00 63.69M
Weighted Average Basic & Diluted Shares Outstanding		 - - - 63.29M 63.29M 63.29M 63.32M 63.32M 63.32M 63.32M

Annual Cash Flow Statements for Guardian Pharmacy Services

This table details how cash moves in and out of Guardian Pharmacy Services' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.15 3.91 61
Net Cash From Operating Activities		 71 58 100
Net Cash From Continuing Operating Activities		 71 58 100
Net Income / (Loss) Continuing Operations		 38 -71 49
Consolidated Net Income / (Loss)		 38 -71 49
Depreciation Expense		 18 20 22
Non-Cash Adjustments To Reconcile Net Income		 -0.74 139 20
Changes in Operating Assets and Liabilities, net		 16 -29 9.46
Net Cash From Investing Activities		 -13 -30 -32
Net Cash From Continuing Investing Activities		 -13 -30 -32
Purchase of Property, Plant & Equipment		 -16 -31 -33
Sale of Property, Plant & Equipment		 2.10 0.67 0.74
Net Cash From Financing Activities		 -57 -24 -7.07
Net Cash From Continuing Financing Activities		 -57 -24 -7.07
Repayment of Debt		 -269 -236 -0.50
Repurchase of Common Equity		 0.00 -59 -31
Payment of Dividends		 -55 -50 -0.46
Issuance of Debt		 270 204 0.00
Issuance of Common Equity		 0.89 123 31
Other Financing Activities, net		 -4.22 -4.64 -6.49
Cash Interest Paid		 2.78 3.12 0.65
Cash Income Taxes Paid		 - 0.00 22

Quarterly Cash Flow Statements for Guardian Pharmacy Services

This table details how cash moves in and out of Guardian Pharmacy Services' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 0.13 -0.58 1.36 36 -33 9.34 4.82 18 29 -0.73
Net Cash From Operating Activities		 15 8.65 29 -2.16 22 18 20 28 35 6.06
Net Cash From Continuing Operating Activities		 15 8.65 29 -2.16 22 18 20 28 35 6.06
Net Income / (Loss) Continuing Operations		 15 7.10 16 -106 12 9.27 8.83 9.59 21 14
Consolidated Net Income / (Loss)		 15 7.10 16 -106 12 9.27 8.83 9.59 21 14
Depreciation Expense		 4.71 4.75 4.87 4.99 5.15 5.27 5.49 5.84 5.74 5.98
Non-Cash Adjustments To Reconcile Net Income		 -21 7.31 1.56 123 6.39 4.72 6.03 5.72 3.04 2.84
Changes in Operating Assets and Liabilities, net		 17 -11 6.86 -25 -1.05 -1.71 -0.41 7.02 4.55 -16
Net Cash From Investing Activities		 -1.15 -3.60 -13 -7.08 -6.62 -5.55 -13 -8.97 -4.71 -4.75
Net Cash From Continuing Investing Activities		 -1.15 -3.60 -13 -7.08 -6.62 -5.55 -13 -8.97 -4.71 -4.75
Purchase of Property, Plant & Equipment		 -2.76 -3.69 -13 -7.34 -6.75 -5.81 -13 -9.21 -4.72 -5.02
Sale of Property, Plant & Equipment		 1.62 0.09 0.19 0.26 0.13 0.26 0.22 0.24 0.01 0.27
Net Cash From Financing Activities		 -13 -5.63 -15 45 -48 -2.67 -2.11 -1.53 -0.76 -2.04
Net Cash From Continuing Financing Activities		 -13 -5.63 -15 45 -48 -2.67 -2.11 -1.53 -0.76 -2.04
Repayment of Debt		 -70 -52 -61 -79 -49 -1.13 - -0.50 - -1.12
Repurchase of Common Equity		 0.25 0.00 -0.16 -56 -3.62 -1.53 -29 - - -30
Payment of Dividends		 -15 -11 -21 -19 0.12 -0.14 -0.05 - -0.27 -0.96
Issuance of Common Equity		 0.35 0.28 0.87 121 0.65 0.14 30 0.39 0.35 30
Other Financing Activities, net		 -1.13 -1.10 -1.08 -1.12 3.31 0.00 -3.09 -1.43 -0.84 -0.04
Cash Interest Paid		 0.70 0.76 1.09 1.01 0.27 0.18 0.17 0.17 0.14 0.15
Cash Income Taxes Paid		 - - - - - 0.06 - 2.90 3.95 2.38

Annual Balance Sheets for Guardian Pharmacy Services

This table presents Guardian Pharmacy Services' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Total Assets		 271 321 413
Total Current Assets		 130 152 222
Cash & Equivalents		 0.75 4.66 66
Accounts Receivable		 77 97 102
Inventories, net		 37 41 43
Other Current Assets		 15 9.62 11
Plant, Property, & Equipment, net		 45 50 56
Total Noncurrent Assets		 96 119 136
Goodwill		 56 69 80
Intangible Assets		 12 15 18
Noncurrent Deferred & Refundable Income Taxes		 0.00 5.27 2.20
Other Noncurrent Operating Assets		 28 29 35
Total Liabilities & Shareholders' Equity		 271 321 413
Total Liabilities		 211 171 195
Total Current Liabilities		 138 144 161
Accounts Payable		 86 102 116
Current Employee Benefit Liabilities		 17 14 15
Other Current Liabilities		 22 27 29
Total Noncurrent Liabilities		 73 27 34
Other Noncurrent Operating Liabilities		 54 27 34
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 60 150 218
Total Preferred & Common Equity		 28 143 206
Total Common Equity		 28 143 206
Common Stock		 0.00 126 139
Retained Earnings		 0.00 17 66
Noncontrolling Interest		 32 7.31 12

Quarterly Balance Sheets for Guardian Pharmacy Services

This table presents Guardian Pharmacy Services' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 348 334 356 390 427
Total Current Assets		 180 166 170 198 235
Cash & Equivalents		 37 14 19 36 65
Accounts Receivable		 91 97 94 106 112
Inventories, net		 45 43 44 48 47
Other Current Assets		 6.89 11 13 7.75 11
Plant, Property, & Equipment, net		 48 51 54 56 57
Total Noncurrent Assets		 120 116 131 136 135
Goodwill		 68 69 76 80 80
Intangible Assets		 15 14 18 19 17
Noncurrent Deferred & Refundable Income Taxes		 5.97 5.27 5.27 4.56 2.20
Other Noncurrent Operating Assets		 30 28 32 33 36
Total Liabilities & Shareholders' Equity		 348 334 356 390 427
Total Liabilities		 214 171 177 195 195
Total Current Liabilities		 158 145 144 162 161
Short-Term Debt		 15 6.67 - - 7.22
Accounts Payable		 107 102 105 122 109
Current Employee Benefit Liabilities		 14 10 17 16 13
Other Current Liabilities		 22 26 22 24 32
Total Noncurrent Liabilities		 56 25 33 33 34
Other Noncurrent Operating Liabilities		 27 25 33 33 34
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 134 163 180 195 232
Total Preferred & Common Equity		 128 156 170 184 221
Total Common Equity		 128 156 170 184 221
Common Stock		 122 130 134 138 141
Retained Earnings		 5.18 27 36 45 80
Noncontrolling Interest		 6.33 7.13 10 12 12

Annual Metrics And Ratios for Guardian Pharmacy Services

This table displays calculated financial ratios and metrics derived from Guardian Pharmacy Services' official financial filings.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - 63,320,634.00
DEI Adjusted Shares Outstanding		 - - 63,320,634.00
DEI Earnings Per Adjusted Shares Outstanding		 - - 0.78
Growth Metrics		 - - -
Profitability Metrics		 - - -
Net Operating Profit after Tax (NOPAT)		 41 -44 48
Return On Investment Capital (ROIC_SIMPLE)		 44.59% -29.37% 22.24%
Earnings before Interest and Taxes (EBIT)		 41 -63 74
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 59 -43 96
Valuation Ratios		 - - -
Leverage & Solvency		 - - -
Liquidity Ratios		 - - -
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 0.00 -98 41
Efficiency Ratios		 - - -
Capital & Investment Metrics		 - - -
Invested Capital		 91 145 152
Increase / (Decrease) in Invested Capital		 0.00 54 6.99
Book Value per Share		 $3.53 $2.25 $3.25
Tangible Book Value per Share		 ($4.98) $0.92 $1.70
Total Capital		 92 150 218
Total Debt		 32 0.00 0.00
Total Long-Term Debt		 19 0.00 0.00
Net Debt		 31 -4.66 -66
Capital Expenditures (CapEx)		 13 30 32
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 3.82 3.20 -4.69
Debt-free Net Working Capital (DFNWC)		 4.57 7.86 61
Net Working Capital (NWC)		 -8.41 7.86 61
Net Nonoperating Expense (NNE)		 3.23 27 -0.48
Net Nonoperating Obligations (NNO)		 31 -4.66 -66
Total Depreciation and Amortization (D&A)		 18 20 22
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.00 ($1.77) $0.00
Adjusted Weighted Average Basic Shares Outstanding		 0.00 62.01M 0.00
Adjusted Diluted Earnings per Share		 $0.00 ($1.77) $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 62.01M 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 63.29M 63.32M
Normalized Net Operating Profit after Tax (NOPAT)		 29 -44 48
Debt Service Ratios		 - - -
Payout Ratios		 - - -

Quarterly Metrics And Ratios for Guardian Pharmacy Services

This table displays calculated financial ratios and metrics derived from Guardian Pharmacy Services' official financial filings.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - 63,294,232.00 - - - 63,320,634.00 63,320,634.00
DEI Adjusted Shares Outstanding		 - - - - 63,294,232.00 - - - 63,320,634.00 63,320,634.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - 0.19 - - - 0.33 0.21
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 19.66% - 19.57% 14.76% 20.05% - 2.21%
EBITDA Growth		 0.00% 0.00% 0.00% -1,566.11% - 47.04% -16.25% 122.72% - 31.71%
EBIT Growth		 0.00% 0.00% 0.00% -1,566.11% - 68.91% -24.57% 116.05% - 38.95%
NOPAT Growth		 0.00% 0.00% 0.00% -1,552.65% - 15.99% -48.12% 112.88% - 42.22%
Net Income Growth		 0.00% 0.00% 0.00% -1,412.75% - 30.70% -44.30% 109.07% - 46.06%
EPS Growth		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 40.00%
Operating Cash Flow Growth		 0.00% 0.00% 0.00% 0.00% - 102.80% -31.57% 1,401.71% - -65.46%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 95.89% - 96.06%
Invested Capital Growth		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 12.95% - 12.10%
Revenue Q/Q Growth		 0.00% 0.00% 8.94% 0.00% - 0.00% 4.56% 9.61% - -15.35%
EBITDA Q/Q Growth		 0.00% 0.00% 72.77% 0.00% - 0.00% -1.59% 24.01% - -34.00%
EBIT Q/Q Growth		 0.00% 0.00% 115.19% 0.00% - 0.00% -3.89% 31.60% - -40.99%
NOPAT Q/Q Growth		 0.00% 0.00% 114.36% 0.00% - 0.00% -4.12% 6.93% - -37.79%
Net Income Q/Q Growth		 0.00% 0.00% 123.37% 0.00% - 0.00% -4.81% 8.68% - -36.31%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% - 0.00% -6.67% 7.14% - 147.73%
Operating Cash Flow Q/Q Growth		 0.00% -40.54% 236.64% 0.00% - -21.43% 13.60% 41.30% - -82.48%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% - 0.00% -3.64% 94.21% - -141.13%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% - 0.00% 3.19% -1.15% - 14.74%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 19.86% 20.01% 20.43% 19.36% - 19.54% 19.79% 19.80% - 22.67%
EBITDA Margin		 -2.39% 4.58% 7.26% -33.28% - 5.63% 5.30% 6.00% - 7.26%
Operating Margin		 -2.41% 2.88% 5.67% -33.27% - 3.95% 3.65% 4.33% - 5.25%
EBIT Margin		 -2.39% 2.85% 5.64% -33.28% - 4.03% 3.71% 4.45% - 5.48%
Profit (Net Income) Margin		 -2.66% 2.58% 5.28% -33.66% - 2.82% 2.56% 2.54% - 4.02%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.17% - 70.75% 70.13% 57.68% - 74.04%
Interest Burden Percent		 111.40% 90.27% 93.70% 100.98% - 98.72% 98.65% 99.05% - 99.17%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% - 29.25% 29.87% 42.32% - 25.96%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% - 45.97% 42.26% 23.17% - 34.24%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% - 44.02% 42.21% 22.09% - 32.83%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% - -1.98% -4.42% -1.99% - -5.39%
Return on Equity (ROE)		 0.00% 0.00% 0.00% 0.00% - 43.99% 37.84% 21.19% - 28.85%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 20.28%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% - 15.48% 13.80% 16.75% - 20.97%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% - 10.81% 9.54% 9.57% - 15.40%
Return on Common Equity (ROCE)		 0.00% 0.00% 0.00% 0.00% - 42.07% 35.71% 20.02% - 27.49%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% - -44.11% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -4.43 7.93 17 -73 12 9.20 8.82 9.43 21 13
NOPAT Margin		 -1.69% 2.88% 5.67% -23.29% - 2.79% 2.56% 2.50% - 3.89%
Net Nonoperating Expense Percent (NNEP)		 0.00% 0.00% 0.00% 947.46% - 1.95% 0.05% 1.08% - 1.41%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - 8.16% 5.42% 4.91% 4.83% 9.65% 5.46%
Cost of Revenue to Revenue		 80.14% 79.99% 79.57% 80.64% - 80.46% 80.21% 80.20% - 77.33%
SG&A Expenses to Revenue		 22.27% 17.13% 14.76% 52.64% - 15.59% 16.14% 15.46% - 17.42%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Operating Expenses to Revenue		 22.27% 17.13% 14.76% 52.64% - 15.59% 16.14% 15.46% - 17.42%
Earnings before Interest and Taxes (EBIT)		 -6.28 7.86 17 -105 17 13 13 17 31 18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -6.28 13 22 -105 22 19 18 23 37 24
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 8.05 - 8.57 7.94 9.05 - 10.86
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 23.35 - 18.39 17.77 19.51 - 19.40
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 - 1.04 1.02 1.20 - 1.65
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 - 0.00 0.00 41.35 - 45.20
Dividend Yield		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 2.42% - 2.21%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 7.39 - 8.58 8.32 10.31 - 13.46
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 - 1.04 1.01 1.18 - 1.62
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 - 0.00 0.00 20.18 - 23.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 - 0.00 0.00 27.56 - 29.68
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 - 0.00 0.00 41.36 - 44.90
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 - 20.00 23.21 18.63 - 26.50
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 70.17
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.33 - 0.04 0.00 0.00 - 0.03
Long-Term Debt to Equity		 0.00 0.00 0.00 0.21 - 0.00 0.00 0.00 - 0.00
Financial Leverage		 0.00 0.00 0.00 0.05 - -0.04 -0.10 -0.09 - -0.16
Leverage Ratio		 0.00 0.00 0.00 2.60 - 2.05 1.98 2.24 - 1.92
Compound Leverage Factor		 0.00 0.00 0.00 2.62 - 2.02 1.96 2.22 - 1.91
Debt to Total Capital		 0.00% 0.00% 0.00% 24.78% - 3.93% 0.00% 0.00% - 3.01%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 8.67% - 3.93% 0.00% 0.00% - 3.01%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 16.10% - 0.00% 0.00% 0.00% - 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 3.56% - 4.20% 5.63% 6.01% - 4.81%
Common Equity to Total Capital		 0.00% 0.00% 0.00% 71.67% - 91.88% 94.37% 93.99% - 92.17%
Debt to EBITDA		 0.00 0.00 0.00 0.00 - -0.18 0.00 0.00 - 0.07
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 - 0.20 0.00 0.00 - -0.56
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 - -0.16 0.00 0.00 - 0.14
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 - 0.18 0.00 0.00 - -1.10
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Altman Z-Score		 0.00 0.00 0.00 0.00 - 8.86 8.64 9.11 - 11.42
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% - 4.37% 5.63% 5.49% - 4.72%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 0.00 0.00 1.14 - 1.14 1.18 1.22 - 1.46
Quick Ratio		 0.00 0.00 0.00 0.81 - 0.77 0.78 0.88 - 1.10
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 0.00 -214 0.00 -147 -152 -8.80 14 -5.78
Operating Cash Flow to CapEx		 0.00% 240.52% 222.32% 0.00% - 316.50% 153.31% 314.18% - 127.62%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -208.58 - -862.86 -883.91 -55.01 - -37.51
Operating Cash Flow to Interest Expense		 0.00 11.31 27.33 0.00 - 103.24 115.91 176.06 - 39.36
Operating Cash Flow Less CapEx to Interest Expense		 0.00 6.61 15.04 0.00 - 70.62 40.30 120.02 - 8.52
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 - 3.84 3.72 3.77 - 3.83
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 - 13.16 14.09 14.10 - 13.93
Inventory Turnover		 0.00 0.00 0.00 0.00 - 23.69 24.14 23.97 - 25.42
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 - 24.91 24.37 26.66 - 26.94
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 - 10.12 10.15 9.76 - 10.95
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 - 27.73 25.90 25.89 - 26.21
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 - 15.41 15.12 15.23 - 14.36
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 - 36.07 35.94 37.40 - 33.32
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 - 7.06 5.07 3.72 - 7.25
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 0.00 0.00 141 145 156 161 159 152 175
Invested Capital Turnover		 0.00 0.00 0.00 0.00 - 16.45 16.49 9.27 - 8.81
Increase / (Decrease) in Invested Capital		 0.00 0.00 0.00 141 0.00 156 161 18 6.99 19
Enterprise Value (EV)		 0.00 0.00 0.00 1,040 - 1,337 1,338 1,639 - 2,353
Market Capitalization		 112 112 112 1,027 - 1,338 1,347 1,664 - 2,399
Book Value per Share		 $0.00 $0.00 $0.00 $2.09 $2.25 $2.47 $2.68 $2.90 $3.25 $3.49
Tangible Book Value per Share		 $0.00 $0.00 $0.00 $0.72 $0.92 $1.15 $1.20 $1.35 $1.70 $1.95
Total Capital		 0.00 0.00 0.00 178 150 170 180 195 218 240
Total Debt		 0.00 0.00 0.00 44 0.00 6.67 0.00 0.00 0.00 7.22
Total Long-Term Debt		 0.00 0.00 0.00 29 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 0.00 0.00 6.88 -4.66 -7.33 -19 -36 -66 -58
Capital Expenditures (CapEx)		 0.00 3.60 13 0.00 6.62 5.55 13 8.97 4.71 4.75
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.00 0.00 0.16 3.20 13 7.65 -0.16 -4.69 17
Debt-free Net Working Capital (DFNWC)		 0.00 0.00 0.00 37 7.86 27 26 36 61 82
Net Working Capital (NWC)		 0.00 0.00 0.00 22 7.86 21 26 36 61 75
Net Nonoperating Expense (NNE)		 2.56 0.84 1.16 33 0.39 -0.07 -0.00 -0.16 -0.23 -0.46
Net Nonoperating Obligations (NNO)		 0.00 0.00 0.00 6.88 -4.66 -7.33 -19 -36 -66 -58
Total Depreciation and Amortization (D&A)		 0.00 4.75 4.87 0.00 5.15 5.27 5.49 5.84 5.74 5.98
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% - 1.05% 0.58% -0.01% - 1.17%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% - 2.14% 2.00% 2.61% - 5.62%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% - 1.62% 2.00% 2.61% - 5.13%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($2.00) ($1.77) $0.15 $0.15 $0.16 ($0.46) $0.21
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 61.14M 62.01M 62.04M 62.05M 62.12M 0.00 63.32M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($2.00) ($1.77) $0.15 $0.14 $0.15 ($0.44) $0.21
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 61.14M 62.01M 62.91M 63.20M 63.43M 0.00 63.69M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 63.29M 63.29M 63.29M 63.32M 63.32M 63.32M 63.32M
Normalized Net Operating Profit after Tax (NOPAT)		 -4.43 5.55 12 -73 12 9.20 8.82 9.43 21 13
Normalized NOPAT Margin		 -1.69% 2.02% 3.97% -23.29% - 2.79% 2.56% 2.50% - 3.89%
Pre Tax Income Margin		 -2.66% 2.58% 5.28% -33.60% - 3.98% 3.66% 4.41% - 5.43%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -8.77 10.27 15.87 -101.96 - 78.09 74.18 104.94 - 119.79
NOPAT to Interest Expense		 -6.19 10.37 15.95 -71.37 - 54.13 51.29 58.96 - 84.98
EBIT Less CapEx to Interest Expense		 0.00 5.57 3.57 0.00 - 45.48 -1.42 48.91 - 88.94
NOPAT Less CapEx to Interest Expense		 0.00 5.67 3.66 0.00 - 21.51 -24.31 2.92 - 54.13
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% - -57.42% -24.61% 0.18% - 2.41%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% - -146.05% -143.18% 86.82% - 113.96%

Financials Breakdown Chart

Key Financial Trends

Guardian Pharmacy Services (NYSE: GRDN) delivered a strong start to fiscal 2026, with improved profitability and positive operating cash flow, but the balance sheet still shows a meaningful working-capital burden and a history of heavy capital needs.

  • Q1 2026 revenue rose to $336.6 million from $329.3 million a year earlier, showing continued top-line growth.
  • Gross profit increased to $76.3 million, up from $64.3 million in Q1 2025, helped by better revenue scale.
  • Operating income improved to $17.7 million versus $13.0 million in Q1 2025, indicating operating leverage is beginning to show through.
  • Net income attributable to common shareholders reached $13.3 million, compared with $9.4 million in the prior-year quarter.
  • Q1 2026 operating cash flow was $6.1 million, turning positive after a weaker cash flow period in late 2025.
  • Cash and equivalents increased to $64.9 million at the end of Q1 2026, up from $36.5 million in Q3 2025 and $13.9 million in Q1 2025.
  • The company continued to generate substantial non-cash earnings support, with depreciation and other non-cash items helping boost cash generation.
  • Quarterly revenue has been fairly steady, ranging from about $329 million to $398 million over the last year, suggesting a relatively stable business base.
  • Selling, general and administrative expense remains high at $58.6 million in Q1 2026, so margin expansion will depend on keeping overhead growth contained.
  • The company still carries a sizable amount of goodwill and intangible assets, which is typical for an acquisition-driven healthcare services model but worth monitoring.
  • Q1 2026 cash flow was pressured by a $16.3 million use of working capital, which offset much of the quarter’s operating profit.
  • The balance sheet shows $160.5 million in current liabilities versus $64.9 million in cash, so liquidity depends heavily on receivables and ongoing operations.
  • Accounts payable was still very large at $108.6 million, underscoring how much of the business is financed through working capital.
  • Capital spending remained meaningful at $5.0 million in Q1 2026, which limits free cash flow conversion.
  • The company has a recent history of large financing swings, including major debt and equity activity in prior periods, which suggests the capital structure can be volatile.

Bottom line: Guardian Pharmacy Services is showing improving earnings and a healthier cash position in early 2026, but investors should keep an eye on working-capital needs and balance sheet pressure. The business appears to be growing, yet cash generation remains somewhat uneven quarter to quarter.

06/26/26 02:12 AM ETAI Generated. May Contain Errors.

Guardian Pharmacy Services Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Guardian Pharmacy Services' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Guardian Pharmacy Services' net income appears to be on an upward trend, with a most recent value of $48.96 million in 2025, rising from $37.72 million in 2023. The previous period was -$71.03 million in 2024. Find out what analysts predict for Guardian Pharmacy Services in the coming months.

Guardian Pharmacy Services' total operating income in 2025 was $72.70 million, based on the following breakdown:
  • Total Gross Profit: $292.72 million
  • Total Operating Expenses: $220.02 million

Over the last 2 years, Guardian Pharmacy Services' total revenue changed from $1.05 billion in 2023 to $1.45 billion in 2025, a change of 38.5%.

Guardian Pharmacy Services' total liabilities were at $194.73 million at the end of 2025, a 14.0% increase from 2024, and a 7.8% decrease since 2023.

In the past 2 years, Guardian Pharmacy Services' cash and equivalents has ranged from $752 thousand in 2023 to $65.62 million in 2025, and is currently $65.62 million as of their latest financial filing in 2025.

Over the last 2 years, Guardian Pharmacy Services' book value per share changed from 3.53 in 2023 to 3.25 in 2025, a change of -7.8%.


Related Companies

Financial statements for NYSE:GRDN last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX IPO “cancelled”?
SpaceX is approaching what could be a $1.6 trillion IPO - potentially the largest in history. But Louis Navell...
InvestorPlace | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
The EPA just put a kill switch on Elon’s empire
A federal EPA permit expires January 2, 2027 - and if Elon Musk's Colossus supercomputer loses power that day,...
Behind the Markets | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Quick favor to ask you
Bill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...
Profits Run | Sponsoredtc pixel
Millionaire trader who went 13-for-13 on Trump in 2025 now turns his attention to Elon.
Hedge fund trader Larry Benedict went 13-for-13 in Q1 2025 - not a single losing trade - and finished the year...
Brownstone Research | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel